methenolone-acetate and Anemia--Aplastic

methenolone-acetate has been researched along with Anemia--Aplastic* in 5 studies

Other Studies

5 other study(ies) available for methenolone-acetate and Anemia--Aplastic

ArticleYear
[Superior sagittal sinus thrombosis presenting with subarachnoid hemorrhage in a patient with aplastic anemia].
    No to shinkei = Brain and nerve, 1998, Volume: 50, Issue:8

    A 54-year-old female, who had been treated for aplastic anemia by metenolone acetate since 1981, developed a sudden unconsciousness in September 1995. On admission, she was drowny, CT showed a subarachnoid hemorrhage (SAH) in the right Sylvian fissure. Angiography demonstrated a complete occlusion of the superior sagittal sinus. The SAH was assumed to be originated from rupture of the right Sylvian vein, which was irregularly dilated on angiography. The dural sinus thrombosis was thought to be caused by a long term use of metenolone acetate, and it was discontinued. But her platelet count dropped due to the aggravation of aplastic anemia, and she developed repeated hemorrhagic infarction. An active anticoagulant therapy for the dural sinus thrombosis was thought to be inappropriate because she had the aplastic anemia and the hemorrhagic infarction recurred. We have successfully treated this case by mild anticoagulant therapy with nafamostat mesilate (Futhan).

    Topics: Anemia, Aplastic; Anticoagulants; Benzamidines; Female; Guanidines; Humans; Magnetic Resonance Imaging; Methenolone; Middle Aged; Sinus Thrombosis, Intracranial; Subarachnoid Hemorrhage; Tomography, X-Ray Computed

1998
[Complete remission of essential thrombocythemia after recovery from severe bone marrow aplasia induced by busulfan treatment].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1997, Volume: 24, Issue:3

    A 63-year-old woman was found to have thrombocythemia and was referred to our hospital for further evaluation in September 1990. Peripheral blood showed platelet 170.0 x 10(4)/microliter, WBC 14,900/microliter and Hb 9.8 g/dl. Bone marrow was hypercellular with increased megakaryocytes and normal karyotype. She was diagnosed as essential thrombocythemia (ET), and treated with 2 mg of busulfan daily for 3 months until her platelet count decreased to 33.1 x 10(4)/microliter. Busulfan was given again for 40 days (a total of 80 mg) in another hospital when the platelet count increased to 71.1 x 10(4)/microliter in September 1991. In December 1991, she was admitted to our hospital because of pancytopenia. Examination of blood revealed platelet 0.4 x 10(4)/microliter, WBC 1,800/microliter and Hb 7.0 g/dl with hypocellular marrow. A diagnosis of busulfan-induced severe bone marrow aplasia was made. We administered metenolone acetate 15 mg and G-CSF 300 micrograms daily. Blood transfusions were given frequently. However, no effect was observed during her hospitalization. After discharge, G-CSF 600 micrograms and erythropoietin 24,000 units were continued twice a week in combination with metanolone acetate. Pancytopenia gradually began to improve as of June 1992, and then trilineage recovery was achieved in March 1994 with platelet 13.3 x 10(4)/microliter, WBC 5,500/microliter and Hb 12.1 g/dl. The platelet count has been within the normal range for more than 2 years after recovery.

    Topics: Anemia, Aplastic; Busulfan; Erythropoietin; Female; Granulocyte Colony-Stimulating Factor; Humans; Methenolone; Middle Aged; Remission Induction; Thrombocythemia, Essential

1997
Images in clinical medicine. Peliosis hepatis.
    The New England journal of medicine, 1997, Nov-27, Volume: 337, Issue:22

    Topics: Aged; Anabolic Agents; Anemia, Aplastic; Fatal Outcome; Female; Humans; Liver; Methenolone; Peliosis Hepatis

1997
Partial remission and severe adverse effect caused by metenolone acetate in a male patient with aplastic anemia.
    European journal of haematology, 1995, Volume: 55, Issue:1

    Topics: Anemia, Aplastic; Cholestasis; Humans; Male; Methenolone; Middle Aged; Remission Induction

1995
Fatal outcome of a patient with severe aplastic anemia after treatment with metenolone acetate.
    Annals of hematology, 1993, Volume: 67, Issue:1

    A 75-year-old man suffering from severe aplastic anemia was treated first with cyclosporin A, then with steroid pulse therapy, and subsequently with metenolone acetate. Marked elevation of transaminases was detected following initiation of treatment with metenolone acetate. This was followed by hepatic failure and death. Histopathological findings in autopsy specimens were compatible with the diagnosis of drug-induced liver impairment, for which metenolone acetate was considered the most likely causative agent. Liver impairment as a side effect of the use of this drug has been thought to be mild, reversible and rather infrequent. However, as demonstrated in the case described here, it is apparent that extreme caution should be exercised when using this drug in debilitated patients.

    Topics: Aged; Anemia, Aplastic; Hepatic Encephalopathy; Humans; Male; Methenolone

1993